Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leaked UK-India Draft FTA Text: Eyes On Provision That Felled Glivec Patent

Executive Summary

A leaked draft intellectual property chapter, purported to be the UK’s opening proposal, from a planned bilateral free trade agreement with India features several controversial provisions. These include nullifying an Indian regulation that disallows patents for "incremental" inventions, requirements around mandatory disclosures on the working of patents, as well as the introduction of data exclusivity. Legal experts weigh in on some of these long-standing contentious issues.

You may also be interested in...



Patent Working Disclosures: Indian PIL Flags Breaches

A public interest litigation (PIL) has brought back to focus a seemingly contentious issue around mandatory disclosures pertaining to the working of patents in India.

Five questions for Novartis India's MD

Novartis India's vice chairman and managing director Ranjit Shahani once joked that almost every passenger even on a "Virar fast local" knows about the company and its anticancer, Glivec (imatinib mesylate), with the backdrop of the Supreme Court ruling last year rejecting a patent for the product and high decibel allegations by activists that the Swiss company was attempting to get the legal framework for examining patent applications in India relaxed.

Syngene COO On Delivering Cost Gains For mRNA Products

Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS147272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel